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MCMVMurine norovirus (MNV) is a recently discovered pathogen that has become a common contaminant of speciﬁc
pathogen-free mouse colonies. MNV-1 induces a robust interferon-β response and causes histopathology in
some mouse strains, suggesting that it may impact other mouse models of infection. Despite many concerns
about MNV-1 contamination, there is little information about its impact on immune responses to other
infections. This study addresses whether MNV-1 infection has an effect on a model of murine cytomegalovirus
(MCMV) infection. Exposure toMNV-1 resulted in a decreased CD8 Tcell response to immunodominantMCMV
epitopes in both BALB/c and C57BL/6 mice. However, MNV-1 did not impact MCMV titers in either mouse
strain, nor did it stimulate reactivation of latentMCMV. These data suggest thatwhileMNV-1 has amild impact
on the immune response toMCMV, it is not likely to affect most experimental outcomes in immunocompetent
mice in the MCMV model.© 2009 Elsevier Inc. All rights reserved.IntroductionAnimal models of infection and disease have been central to the
study of pathogenesis, vaccine development, and drug treatment.
While there are drawbacks to these models—particularly that they
may not precisely model human disease—they are indispensable for
making precise statements about the agent being studied, because
they allow the investigator to control confounding variables. The
timing and dose of infection can be strictly controlled, the impact of
genetic polymorphisms is controlled by use of inbred mouse strains,
mutant pathogens and animals can be generated, and exposure of
animals to other pathogens can be controlled by housing them in
speciﬁc pathogen-free (SPF) facilities.
SPF facilities are particularly important for immunological and
pathogenesis studies, as unintentional infections can alter immune
system functioning and confound experiments using other infectious
agents. Use of SPF mice for this sort of study has been virtually
universal for decades. SPF mice are typically screened for pathogens
such as mouse parvovirus (MPV) and mouse hepatitis virus (MHV)
that are known to spread endemically and affect experimental results
(Biggart and Ruebner, 1970; Bonnard et al., 1976; McKisic et al., 1993;
Riley et al., 1960; Rowe et al., 1959). But how dowe deﬁne a pathogen?
Agents that cause overt disease in healthy animals are automatically
classiﬁed as pathogens and are excluded from animal facilities.
However, a range of other microorganisms can colonize animals,n Park Dr, L220, Portland, OR,
l rights reserved.including normal gastrointestinal ﬂora, some of which can cause
disease in immunocompromised animals. Some agents, such as Heli-
cobacter (H.) hepaticus and H. bilis are part of the regular screens
performed to monitor SPF facilities, and yet they are not eradicated by
many facilities, including our own. Eradication of agents from a facility
can be extremely costly, frequently requiring elimination of most of
the colony and rederivation of breeder stock. In practice, investigators
and facility managers are generally motivated to eradicate new agents
by evidence that the agents impact experimental outcomes.
Karst et al. discovered murine norovirus (MNV) in conventionally
housed mice at Washington University by a screen for novel human
pathogens capable of infecting mice (Karst et al., 2003). MNV-1 was
subsequently isolated and identiﬁed as the ﬁrst calicivirus to infect
rodents. It has since been suggested that MNV infection of laboratory
mice is endemic, presumably being spread by the oral-fecal route as in
humans (Perdue et al., 2007). A recent study of mice in research
facilities within North America found that 22% of serum samples were
MNV-seropositive, making MNV the most common mouse colony
contaminant known (Hsu et al., 2005). Caliciviruses are single-
stranded, positive-sense RNA viruses that are non-enveloped and
non-segmented. There are ~7400 base pairs that code for three open
reading frames (ORFs) and eight known proteins. The original strain
was namedMNV-1; 26MNV-1 genomes have since been isolated from
different institutions around the world and sequenced (Karst et al.,
2003; Thackray et al., 2007). Of the 15 unique strains identiﬁed by
Thackray et al., there is amaximumof 13% nucleotide divergence at the
whole genome level (Thackray et al., 2007). Minor amino acid changes
can quite signiﬁcantly impact the virulence of strains, as mutation in
only two amino acids can attenuate a virulent strain (Bailey et al.,
2008). Currently, all known strains form a single genotype, genogroup,
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reactivity exists, because infection with any of the isolated strains can
be identiﬁed using a single antibody (Hsu et al., 2006; Lochridge and
Hardy, 2007; Thackray et al., 2007).
There has been much concern, particularly in the immunology
community, about the potential impact of MNV on infection and
disease models in mice and thus, the need for its eradication. As a
consequence, we embarked on the current study to investigate how
MNV-1 impacts the outcome of experiments carried out in our own
laboratory, which focuses on immunity to murine cytomegalovirus
(MCMV). MNV seems most likely to pose a problem for experiments
involving the immunological pathways that are important for its
control. It is clear that the interferon (IFN) response is important in this
regard, as MNV-1 infection is lethal to mice that lack the receptors for
both type I and type II interferons (IFN-α/β/γR−/−). MNV-1 is also
lethal tomice that lack signal transducer and activator of transcription
(STAT)-1, a transcription factor activated by IFN signaling that
ultimately induces expression of interferon stimulated genes (ISG)
(Karst et al., 2003).MNV is not lethal, however, tomice that have either
the IFN-αβ (type I) or the IFN-γ (type II) system intact (Karst et al.,
2003; Muller et al., 2007). Mice that lack other aspects of the innate or
adaptive immune systems, such as inducible nitric oxide synthase
(NOS−/−) or protein kinase RNA-activated (PKR)−/− and recombina-
tion-activating gene (RAG)-1−/− or RAG-2−/−, respectively, do not
succumb to infection (Karst et al., 2003).
MNV can be either acute or persistent; persistence is both virus
strain- and mouse strain-speciﬁc. For example, wild type 129/SvJ
mice clear MNV-1 CW after acute infection, but 129/SvJ RAG-2−/−
mice are persistently infected with MNV-1 CW and have viral RNA in
multiple tissues up to 90 days post-infection (p.i.) (Karst et al., 2003).
C57BL/6 RAG-1−/− mice are also “chronic secreters” of MNV-1 CW,
but wild type C57BL/6 mice clear the virus by day seven p.i. (Karst et
al., 2003; Thackray et al., 2007). Strains that are acutely cleared in
wild type animals include MNV-1 CW1, CW3, andWU11, while strains
CR1, CR3, CR6, and CR7 have been shown to be persistent (Thackray et
al., 2007).
MNV infection is not as symptomatic in mice as its human counter-
part, which causes gastrointestinal illness. There are a few examples
where mice show overt signs of infection, however. Before STAT-1−/−
mice succumb to MNV-1 CW3 infection, they display gastrointestinal
symptoms, including diarrhea, decreased gastric emptying, and
decreased fecal weight contents, in addition to splenitis and
pneumonia at 72 h p.i. (Karst et al., 2003; Mumphrey et al., 2007).
While MNV-1 infection has a clear impact on the morbidity and
mortality of some immunodeﬁcient, knock-out mice, the nature of
infection and the immune response in immunocompetent animals is
still under investigation. MNV-1 CW3-infected C57BL/6 and 129/SvJ
mice are asymptomatic, but infected 129/SvJ mice have evidence of
splenic red pulp hypertrophy and granulocyte inﬁltration in the
intestine at three days p.i. (Mumphrey et al., 2007). Viral RNA is
detectable in the liver, spleen, and intestine up to three days p.i. in 129/
SvJ mice and up to seven days p.i. in C57BL/6 mice (Karst et al., 2003;
Mumphreyet al., 2007).MNV-1 infection induces a strong serum type I
IFN response in 129/SvJ mice, which peaks at 24 h p.i. (Thackray et al.,
2007). This cytokine response suggests that silentMNV infection could
have a strong and polarizing effect on the immune system of
immunocompetent mice.
MNV is present in most laboratory mouse colonies in North
America, but now most major commercial suppliers are free of MNV.
The virus is thought to be readily transmitted by fecal dust that is
spread by normal handling of mouse cages. Thus, mice purchased for
experiments have a signiﬁcant chance of undergoing acute MNV
infection at some stage during an experiment. Another laboratory at
our institution experienced a dramatic change in the LD50 of their
mice for West Nile virus (WNV) that appeared to coincide historically
with the appearance of MNV in the colony (Janko Nikolich-Zugich,personal communication). This raised the suspicion that inadvertent
MNV infection could seriously impact interpretation of other
infectious models. Our laboratory routinely infects mice with the β-
herpesvirus MCMV, which establishes lifelong infection and is often
used to study immune evasionmechanisms and the immune response
to a latent viral infection. We measure the CD8 T cell response by
cytokine production and viral control by comparing titers in various
organs. There is natural variability in this system, and we have the
impression that responses and titers seem to be higher amongst an
entire experimental cohort in some experiments than in others
(Doom and Hill, 2008). The variability is greater than might be
expected using inbredmice and standard, tissue culture-derived virus.
When MNV was added to the panel of agents for which our sentinel
mice are routinely tested, we became aware of the presence of MNV in
our mouse colony. We therefore wondered whether MNV contamina-
tion of our experimental mice was responsible for some of the
variation we see in our model.
The following study was performed in order to assess the effect of
MNV on MCMV infection and the ensuing immune response. We
tested two strains of mice (BALB/c and C57BL/6) and two strains of
MNV (one persistent, one acute), varying the timing of both infections
to model potential random MNV contamination. We did not ﬁnd a
dramatic impact of MNV on MCMV infection or the immune response
to it under most conditions. However, MNV did impact the size of the
CD8 T cell response to MCMV during acute infection in immunocom-
petent animals.
Results
Handling of mice to avoid inadvertent MNV infection
Because these experiments were performed in an animal room in
which some sentinel mice had tested positive for MNV, it was
important to prevent accidental MNV infection of the study mice.
MNV is thought to be transmitted by means of infectious fecal
material spreading through the air as dust. To prevent inadvertent
infection, we followed procedures established by the Virgin
laboratory. Mice were housed in standard cages with ﬁlter tops
and were only handled in a biosafety cabinet dedicated to these
experiments and only by two individuals who did not handle other
mice in the colony. All cage equipment was autoclaved as a unit and
stored in the autoclave bag, which was opened in the biohazard
cabinet to prevent exposure to airborne fecal dust. The water was
autoclaved and supplied in individual bottles and all food was
irradiated. Surfaces and supplies were disinfected before and after
use for at least 10 min in a 10% bleach solution. Whenever mice were
handled, infected, or harvested, naïve mice were handled ﬁrst,
followed by MCMV-infected mice, followed by MNV (±MCMV)
infected mice. Mice were tested for MNV seropositivity before use in
an experiment and on the day of sacriﬁce. Seroconversion generally
occurs by day 21 p.i, but does not peak until at least day 35 p.i. (Karst
et al., 2003; Thackray et al., 2007); therefore, serological testing
could not exclude inadvertent infection for many experiments. In
total, 272 mice were used in this study. Over half of them (152) were
in the facility for greater than 21 days; the average length of time in
the facility before sacriﬁce was 63 days. For all of these experiments,
the only mice that were seropositive at sacriﬁce were mice that had
been intentionally infected with MNV. Furthermore, no sentinels
from the rack of mice used in these experiments tested positive for
MNV. Therefore, although we cannot conclusively exclude the
possibility of inadvertent MNV infection shortly before sacriﬁce, it
is likely that the vast majority of the control mice (MNV-non-
infected) in this study remained MNV-free. We know that mice
intentionally administered MNV were productively infected, how-
ever, as 17/20 mice infected with MNV for at least 23 days were
MNV-seropositive (data not shown).
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viral titers
We considered that mice purchased commercially arrive at our
facility free of MNV, but may become infected at any time thereafter.
We thought that MNV would be most likely to impact our
experimental results if acute MNV infection occurred around the
time of initial infectionwithMCMV. Hence, the ﬁrst set of experiments
(Fig. 1) tested whether MNV infection at the time of or immediatelyFig. 1.MNV infection does not alter the magnitude of MCMV infection. A) BALB/c (i.–iii.) or C
or day 0. On day 0, mice were infected i.p. with 5×105 PFU MCMV MW97.01. Four days late
DMEM-complete and the other organs were snap frozen in liquid nitrogen. MCMV titers in di
dot represents an individual mouse; the short, solid line represents the mean. The limit of de
numerals (i.–iv.) represent similar experiments performed on different days. MNV was given
ii. and iii. MNV was given on day−2 in BALB/c iii. and C57BL/6 iv. All mice were MNV-seron
N0.100, unless otherwise noted. In each case where there was a signiﬁcant difference betwe
signiﬁcant difference was found.before MCMV would impact the course of MCMV infection. We
infected mice by mouth with MNV-1 strain CW3, which causes acute,
cleared infection in immunocompetent mice, and then infected these
and control mice i.p. with MCMV, either the same day or one or
two days later. We used the BAC-derived MCMV-Smith strain
MW97.01 (Wagner et al., 2002) (5×105 PFU). We tested both BALB/
c and C57BL/6 mice, which differ greatly in their ability to control
acute MCMV infection due to a difference in efﬁcacy of the NK cell
response. MCMV titers were measured in multiple organs at day four57BL/6 (i.–iv.) mice were infected p.o. with 3×107 PFUMNV-1 CW3 on day−2, day−1,
r (d 4) mice were sacriﬁced. The salivary glands and spleen were harvested into 1 mL
fferent organs were tested by standard plaque assay using 10% tissue homogenates. Each
tection is 101 PFU and is indicated by the dotted line. n=5 or 12 for each group. Roman
on day 0 in BALB/c i. and C57BL/6 i. MNVwas given on day−1 in BALB/c ii. and C57BL/6
egative. All p-values comparing organ virus titers with and without MNV infection were
en organ virus titers, there is an example provided from a similar experiment where no
Fig. 2.MNV infection does not alter the kinetics of MCMV infection. C57BL/6 or BALB/c mice were infected p.o. with 3×107 PFU MNV-1 CW3 on day−2. On day 0, mice were ected i.p. with 5×105 PFU MCMVMW97.01. A) 3, 7, and 14 days
later or B) 21 days later, micewere sacriﬁced. C) C57BL/6micewere infected p.o. with 108 PFUMNV-1 CR6 (passage 2) on day−2. On day 0, micewere infected i.p. with 5×105 UMCMVMW97.01. Twenty-one days later, micewere sacriﬁced.
The salivary glands and spleenwere harvested into 1mL DMEM-complete and the other organs were snap frozen in liquid nitrogen. MCMV titers in different organs were teste y standard plaque assay using 10% tissue homogenates. Each dot
represents an individual mouse; the short, solid line represents the mean. The limit of detection is 101 PFU and is indicated by the dotted line. n=5 for each group. B) i–ii. rep ent identical experiments performed on different days. All mice
were MNV-seronegative, except in B) 12/15 MNV-infected mice were MNV-seropositive and C) 5/5 MNV-infected mice were MNV-seropositive. All p-values comparing orga irus titers with and without MNV infection were N0.200, unless
otherwise noted.
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Fig. 3. MNV infection impacts the immunodominant CD8 T cell response to MCMV.
BALB/c mice were infected p.o. with 3×107 PFUMNV-1 CW3 on day−2. On day 0, mice
were infected i.p. with 5×105 PFUMCMVMW97.01. Aweek later (d 7), the spleens were
harvested and splenocytes were incubated with MCMV peptides (10−6 M) for 7 h in the
presence of brefeldin A. Theywere then stained for surface CD8-α, ﬁxed, permeabilized,
and stained for intracellular IFN-γ. The percentage of IFN-γ+ CD8-α+ T cells were
measured by ﬂow cytometry on an LSR II and analyzed by FloJo software. Error bars
indicate SEM. n=6 for each group. All mice were MNV-1 seronegative. All p-values
comparing an epitope-speciﬁc response with and without MNV infection were N0.100,
unless otherwise noted.
157C.M. Doom et al. / Virology 392 (2009) 153–161p.i., the peak of acute infection; the results are shown in Fig. 1. As
expected, MCMV titers were much higher in BALB/c than in C57BL/6
mice. These results also illustrate the variability between experi-
ments that we sometimes see in this model (e.g. compare the
spleen titers in Fig. 1 i.), which we had thought might be explained
by concomitant MNV infection. Occasionally, comparisons revealed
a small but signiﬁcant difference between titers in individual
organs within an experiment. For example, in Fig. 1 C57BL/6 ii., 4/12
mice infected with MCMV only had MCMV detectable in the liver
(mean titer=125 PFU), while 10/12 mice infected with MCMV
+MNV had MCMV detectable in the liver (mean titer=220,
p=0.0098). However, in the same experiment, no other organs
showed a signiﬁcant difference in titers. Furthermore, in a parallel
experiment (Fig. 1 C57BL/6 iii.), the titers did not differ in the liver
(0.5476). Overall, there was no consistent impact of concomitant
MNV infection on MCMV titers at day four p.i. In addition, acute
titers of the more virulent MCMV-K181 strain were not impacted by
MNV-1 CW3 exposure two days prior to MCMV infection (2×105
PFU, i.p.) in C57BL/6 mice (data not shown).
After day four, virus titers decline in most organs, and MCMV
MW97.01 appears in the salivary glands at about two weeks p.i. In
BALB/c mice, virus persists in the salivary glands until about four
weeks p.i. Even though uncloned MCMV-Smith can persist in the
salivary glands of C57BL/6 mice, we have found salivary glands
infection of C57BL/6 mice with the BAC-derived MW97.01 strain to be
frequently undetectable. We investigated the impact of MNV on the
kinetics of acute MCMV infection in C57BL/6 mice, on days three,
seven, and 14 p.i. (Fig. 2A). The potential impact of MNV infection on
the peak of MCMV salivary glands infection (21 days post-MCMV) in
both BALB/c and C57BL/6 mice was also investigated (Fig. 2B). In none
of these experiments did we see an impact of MNV.
Finally, we also tested a persistent strain of MNV. MNV-1 CR6
(passage 2) persists in the distal ilea and mesenteric lymph nodes of
C57BL/6 mice up to 35 days p.i. (Thackray et al., 2007). At 21 days
post-infection with MCMV, despite ongoing MNV shedding in the
feces (detected by PCR, data not shown), no MCMV was detected in
any organ except for the kidney (Fig. 2C). Together, the experiments
in Figs. 1 and 2 provide no consistent evidence that MNV impacts the
early course of laboratory MCMV infection in immunocompetent
mice.
Acute MNV affects the acute, immunodominant CD8 T cell response
to MCMV
While MCMV virus titers were not impacted by concurrent MNV
infection, it was possible that MNV infection could affect the CD8 Tcell
response to MCMV. The CD8 T cells response can be affected by-
cytokines, including IFN-α and IL-12, and MNV has been shown to
induce a strong type I IFN response in 129/SvJ mice, which peaks at
24 h p.i. (Mumphrey et al., 2007). Furthermore, it is possible that MNV
would impact the CD8 T cell response toMCMV infection if there were
any cross-reactive epitopes (Brehm et al., 2002; Selin et al., 1994). The
MCMV-speciﬁc CD8 Tcell response is robust and well-characterized. It
peaks at day seven p.i. and the immunodominant epitopes to which
CD8 T cells respond are known in both BALB/c and C57BL/6 mice
(Holtappels et al., 2002a, 2002b; Munks et al., 2006; Reddehase and
Koszinowski, 1984; Reddehase et al., 1986). Mice (C57BL/6 or BALB/c)
were infected with MNV-1 CW3 and control mice were infected two
days later with MCMV. Seven days later the CD8 T cell response was
measured in splenocytes by intracellular cytokine staining (ICCS) for
IFN-γ (Fig. 3). In BALB/c mice, the percentage of IFN-γ+ CD8+ T cells
speciﬁc for the two most immunodominant peptides, IE1 (pp89) and
m164, was modestly but signiﬁcantly lower in mice infected with
MNV (p=0.005 and p=0.0003, respectively). The same result was
seen in two separate experiments using T cells isolated from the
peripheral blood (data not shown). Similarly, in C57BL/6 mice, themagnitude of the response to the most immunodominant peptide,
M45, was lower in MNV-infected mice (p=0.045). The immunodo-
minance hierarchy was not affected by MNV in either mouse strain.
Thus, concomitant MNV infection did affect the CD8 T cell response to
MCMV infection, although the impact was modest.
MCMV does not reactivate in response to MNV infection
By four weeks p.i., the BAC-derived MCMV MW97.01 is generally
undetectable in any organ by plaque assay although latent infection,
and perhaps undetected persistent replicative infection, continues.
Reactivation of latent MCMV is an important, yet still poorly un-
derstood, part of the infectious cycle that can be experimentally
induced by a number of stimuli (Cook et al., 2002, 2006; Koffron et al.,
1999; Simon et al., 2005). Notably, inﬂammatory stimuli, such as
bacterial infection, LPS, TNF-α, and IL-1, have been shown to induce
CMV reactivation. We have sometimes found several mice in a single
cage with MCMV in the spleen or other organs at a time p.i. at which
the virus is usually undetectable, which has bedeviled experimental
reproducibility and made us suspect a non-random adventitious
event. Since MNV infects some of the cell types in which MCMV has
been shown to be latent (Hanson et al., 1999; Koffron et al., 1998;
Mercer et al., 1988; Pollock et al., 1997; Pomeroy et al., 1991; Wobus et
al., 2004), and since it induces inﬂammatory cytokines, we thought it
possible that MNV may induce reactivation of latent MCMV. In order
to test this, mice were infected with MCMV MW97.01 for at least four
weeks, after which half of the mice were also infected with acute
MNV-1 CW3. MCMV reactivation models have different peaks of
reactivation depending on the stimulus used, therefore, viral titers
158 C.M. Doom et al. / Virology 392 (2009) 153–161were measured at either one or two weeks post-MNV in the salivary
glands, lung, and spleen, the organs in which MCMV reactivation is
most readily detected (Balthesen et al., 1993). However, we detected
no difference in viral titers in the presence or absence of MNV
stimulation in either BALB/c (Fig. 4A) or C57BL/6 mice (Fig. 4B).
MCMVMW97.01 is somewhat attenuated compared to either Smith or
K181 strains of MCMV (unpublished data). We therefore repeated the
reactivation experiments with the more virulent K181 strain (Fig. 4C).
K181 caused persistent infection of the salivary glands in C57BL/6
mice, as has been reported (M. Degli-Esposti, unpublished data).
However, MNV infection did not cause any alteration of virus titers to
indicate reactivation in either C57BL/6 or BALB/c mice.
Discussion
This study was undertaken in order to determine whether the
recently discoveredmouse pathogen, MNV, had an impact on a mouseFig. 4.MCMV MW97.01 does not reactivate in response to MNV infection. A) BALB/c or B) C5
micewere infected p.o. with 3×107 PFUMNV-1 CW3. Either 1 (left panels) or 2 (right panels)
i.p. with 5×105 PFUMCMV-K181 on day≥30. On day 0, mice were infected p.o. with 3×107 P
lung were harvested into 1 mL DMEM-complete. MCMV titers in these organs were tested by
mouse; the short, solid line represents the mean. The limit of detection is 101 PFU and is ind
values comparing organ virus titers with and without MNV infection were N0.400, unless omodel of MCMV infection. MNV is a common infection in mouse
colonies around the world; there is much concern regarding this
emerging pathogen but little published data on its impact on other
infectious agents or models. Recently, Hensley et al. reported that the
persistent MNV-1 CR6 strain has no signiﬁcant impact on the immune
response to acute vaccinia or inﬂuenza viruses (Hensley et al., 2009).
We wanted to investigate a possible impact of MNV on our in vivo
model of MCMV infection, because there is a degree of variability that
has always been puzzling. The variation segregates by experimental
day and often by cage. Mice infected with the same dose on different
days may haveMCMV titers in their salivary glands that differ by up to
two logs at 21 days p.i. This kind of variability could be explained by
inadvertent infection with another agent. Upon learning that sentinel
mice in our colony were MNV-seropositive, we were keen to see
whether MNV was responsible. It is important to note that the
experiments performed for this study were solely concerned with the
outcomes of MCMV infection—our own experimental system—and we7BL/6 mice were infected i.p. with 5×105 PFU MCMV MW97.01 on day ≥30. On day 0,
weeks later, micewere sacriﬁced. C) BALB/c (left) or C57BL/6mice (right) were infected
FUMNV-1 CW3. Twoweeks later, mice were sacriﬁced. The salivary glands, spleen, and
standard plaque assay using 10% tissue homogenates. Each dot represents an individual
icated by the dotted line. n=5 for each group. All mice were MNV- seronegative. All p-
therwise noted.
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assess the effect of MNV-1 onMCMV infection, twowell-characterized
outcomes of infection were measured: the MCMV-speciﬁc CD8 T cell
response and MCMV viral titers.
We focused primarily on the impact of MNV infection occurring
around the time of MCMV infection, which we thought would be
most likely to affect our experimental outcomes. However, we could
not detect a consistent impact of MNV on acute MCMV infection, or
on persistent infection of the salivary glands. Furthermore, acute
MNV infection did not drive detectable reactivation of latent MCMV.
We can cautiously conclude that MNV does not have a large impact
on the course of MCMV infection in immunocompetent mice and is
unlikely to be a major contributor to experimental variation within
our model system. The cause of our experimental variation remains
to be determined; possible explanations that have not yet been
addressed include adventitious infection with a currently unknown
agent (it is unlikely that MNV will be the last such agent to be
identiﬁed), differences in commensal ﬂora between commercial mice
and those bred in our facility, and the impact of the estrus cycle (as
we predominantly use female mice).
There are possible caveats to this conclusion, which is based on
experimental infection with two laboratory-passaged strains of MNV.
A growing number of MNV strains have been identiﬁed that possess
different characteristics regarding persistence, etc., and it has also been
reported that it does not takemany generations for the phenotype of a
strain to change quite drastically (Bailey et al., 2008; Mumphrey et al.,
2007; Thackray et al., 2007). The strains that have spontaneously
contaminated our mouse colony on the West coast may have very
different characteristics than those propagated for use in this study.
Nevertheless, we used high dose infection of the originally isolated
MNV-1 strain (CW3) without detecting any impact on the course of
MCMV infection. Furthermore, infection with a very different MNV
strain (CR6), which causes chronic infection in C57BL/6 mice, also
failed to impact acute MCMV infection.
We did, however, reproducibly detect a small but signiﬁcant impact
of MNV infection two days prior to MCMV on the size of the CD8 T cell
response to the most immunodominant epitopes in both BALB/c and
C57BL/6 mice. Curiously, there was no impact on the magnitude of the
CD8 T cell response to subdominant peptides, nor were there any
changes in the hierarchy itself. As there was no increase in the size of
the response to a particular MCMV epitope or the immunodominance
hierarchy, in general, there was no evidence for cross-reactive
epitopes. As yet, CD8 Tcell responses toMNV have not been described.
The characterization of innate immune control of MNV is incomplete,
but it is known that MNV-1 infection induces a strong serum type I IFN
response in 129/SvJ mice, which peaks at 24 h p.i. (Mumphrey et al.,
2007). The CD8 T cell response is known to be regulated in part by
inﬂammatory cytokines, including type I IFN, and we suspect that the
impact of MNV on the cytokine milieu present at the time of CD8 T cell
primingmay be responsible for its impact on the CD8 Tcell response to
MCMV. This impact was rather small, and would not alter the
interpretation of most experiments. Nevertheless, it should be borne
in mind, particularly for studies on immunodominance and the size of
the CD8 T cell response.
Our study with MCMV cannot predict the impact that MNV might
have on other infectious models. Furthermore, we used only
immunocompetent mice. MNV is much more likely to impact studies
using immunologically impaired mice, since it is lethal for mice
severely impaired in interferon responses. Further investigations are
needed before the overall impact of this agent is clear. In themeantime,
MNV remains a non-random variable that is superimposed on our
experiments. Mice purchased from commercial vendors are free from
MNV, whereas strains bred in-house at many facilities may be
contaminated. In particular, immunodeﬁcient mutant strains are
more likely to be chronic carriers. Given these considerations, even
without direct evidence of the impact ofMNVon experimentalmodels,it is likely that many facilities will decide to eradicate MNV, as some
already have. Eradication of MNV from most facilities will require
embryonic rederivation of mouse strains that cannot be purchased
commercially and is an expensive undertaking. It is of course highly
unlikely that MNV is the last “adventitious”murine infection that will
be discovered. A side beneﬁt of rederivation of a colony is that it will
likely remove other as yet undiscovered agents in addition to MNV.
While the immune systems of inbred SPFmice may imperfectly model
those of animals in the wild, rigorous control of variables using these
mice has enabled remarkable progress in theﬁnedissectionof immune
responses. At present, the signiﬁcance of MNV as a variable for
different experimental outcomes remains to be determined.
Materials and methods
Cells
BALB/c 3T3 ﬁbroblasts (ATCC) were cultured in Dulbecco
modiﬁed Eagle medium (DMEM) supplemented with 10% Fetalplex
(Gemini Bio-Products, West Sacramento, CA), 2 mM L-glutamine,
100 U penicillin/mL, and 100 μg/mL streptomycin. The mouse
macrophage cell line, RAW 264.7 (a kind gift from Fred Heffron,
OHSU) was cultured in DMEM supplemented with 10% fetal bovine
serum (FBS), 2 mM L-glutamine, 10 mM HEPES, and antibiotics
(“DMEM-complete”).
Viruses
Wild-type (WT) BAC-derived MCMV strain MW97.01 was grown
on C57BL/6mouse embryonic ﬁbroblasts (MEF) using a multiplicity of
infection (MOI) of 0.01. Virus was puriﬁed by ultracentrifuging
through a 15% sucrose cushion. Mice were infected by intraperitoneal
(i.p.) injectionwith 5×105 plaque-forming units (PFU) in a volume of
200 μL unless otherwise stated. MCMV strain K181 (a kind gift from Ed
Mocarski, Stanford University, CA)was grown on C57BL/6MEFs. Crude
viral lysates were frozen and thawed three times and aliquoted. Mice
were infected i.p. with 2×105 PFU in a volume of 600 μL. Each virus
stock was titered on BALB/c 3T3 cells. The ﬁnal virus titers were
calculated by taking the mean of 3 virus titrations.
MNV-1 CW3 and passage 2 of MNV-1 CR6 (both kind gifts from
Skip Virgin, Washington University, MO) were grown on RAW 264.7
cells at an MOI of 0.05. Cell lysates were frozen and thawed three
times and clariﬁed by centrifugation at 3000 rpm for 20 min. For
concentrated stocks, lysates were centrifuged at 27,000 rpm for 3 h at
4 °C. Each virus stock was titered on RAW 264.7 cells as described
(Wobus et al., 2004). The ﬁnal virus titers were calculated by taking
the mean of three virus titrations. Mice were infected orally (p.o.)
with 3×107 PFU in a volume of 10 μL, unless otherwise speciﬁed.
Mice
Female C57BL/6 and BALB/c mice were purchased from The
Jackson Laboratory (Bar Harbor, ME) or Charles River Laboratories
(Wilmington, MA), both certiﬁed MNV-free vendors. All mice were
maintained according to institutional and federal guidelines in animal
facilities at Oregon Health and Science University (Portland, OR). Mice
were given access to food and water ad libitum and housed in a
speciﬁc-pathogen-free facility that monitors sentinel animals for 13
different pathogens every three months. None of the sentinels for the
animals used in these experiments were ever positive for any of the
monitored pathogens. Mice were used in experiments between 7 and
12 weeks of age. At sacriﬁce, all organs were aseptically removed. The
spleen and salivary glands were harvested into 1 mL of DMEM-
complete and any other organs were snap frozen in liquid nitrogen.
The spleen and salivary glands were homogenized the day of the
experiment using tissue grinders (Wheaton, Millville, NJ). Snap frozen
160 C.M. Doom et al. / Virology 392 (2009) 153–161organs were thawed, suspended in 1 mL of DMEM-complete (except
for the liver, which was suspended in 2 mL) and homogenized. All
homogenates were stored at −80 °C and frozen and thawed 3 times
before use.
Intracellular cytokine staining and ﬂow cytometry
Splenocytes or peripheral blood mononuclear cells (PBMC) were
isolated from MCMV-infected mice and incubated with 10−6 M
MCMV peptides (Jerini, Berlin, Germany) or a no-peptide control for
6 h at 37 °C in the presence of brefeldin A (GolgiPlug; BD PharMingen,
San Diego, CA), as described (Munks et al., 2006). Cells were washed
and surface stained with PE-Cy5-conjugated anti-CD8-α (clone 53-
6.7; eBioscience, San Diego, CA). Cells were then ﬁxed and
permeabilized using BD PharMingen's Cytoﬁx/Cytoperm kit before
staining with PE-conjugated anti-IFN-γ (clone XMG.1; eBiosciences).
Cells were acquired by ﬂow cytometry on an LSR II (BD Bioscience,
Franklin Lakes, NJ) using Cell Quest acquisition software (BD
Bioscience). All further data analysis was done using FlowJo software
(Treestar, San Carlos, CA).
MCMV plaque assay
BALB/c 3T3 cells were seeded at 1.5×105 cells/well in six-well
plates (Falcon) and grown overnight in DMEM-complete. Ten percent
organ homogenates were clariﬁed by centrifugation and added in 10-
fold dilutions to 1 mL of freshly-replaced media/well. Ninety minutes
later, themediawas removed and thewells were overlaid with 4mL of
a 3:1 mixture of media and 15% w/v carboxymethylcellulose (CMC;
Sigma). On day 6, the plates were rinsed with PBS and stained with
0.1% crystal violet in 1% formalin (Fisher) for 5 min. The plates were
rinsed again in PBS and allowed to dry. Plaques were then visualized
on a light source and counted. Plaques detected on 3T3 cells were
MCMV and not MNV, because (a) MNV can only cause cytopathic
effects (CPE) in 3T3 cells at extremely high MOI and (b) all plaques
detected on 3T3 cells from dually infected mice were positive for the
MCMV protein pp89 by immunoﬂuorescence (not shown).
MNV plaque assay
Plaque assays for MNVwere performed as described (Wobus et al.,
2004). Brieﬂy, RAW 264.7 cells were seeded at 2×106 cells/well in six-
well plates and grown overnight. Either puriﬁed virus preparations or
10% organ homogenates that had been clariﬁed by centrifugationwere
added in 10-fold dilutions to 500 μL of freshly-replaced media/well.
After rocking for 1 h at room temperature, each well was overlaid with
2 mL of a 1:1 mixture of 2× MEM and 3% Seaplaque (Lonza, Basel,
Switzerland). Two days later, eachwell was overlaid with 2mL of a 1:1
mixture of 2× MEM, 3% SeaKem (Lonza), including 0.01% neutral red
dye. Twelve hours later, plaques were visualized by microscope and
counted.
Enzyme-linked immunosorbent assay (ELISA)
All sera for ELISAs were collected by retro-orbital bleed. Blood
samples were allowed to coagulate overnight at 4 °C and then were
spun at 2 rpm for 20 min. The sera were aliquoted into multiple tubes
for further use. To test for MNV seropositivity, high-binding Immulon
4HBX microtiter plates (Thermo, Milford, MA) were coated with
puriﬁed MNV. Puriﬁed MNV was prepared as described by Wobus et
al. with some modiﬁcation (Wobus et al., 2004). Brieﬂy, RAW 264.7
cells were seeded at 4×107 cells/well in T175 ﬂasks and grown
overnight. The cells were infected at an MOI of 0.05 with MNV-1 CW3
and incubated for 48 h. The cells and supernatant were harvested and
frozen (−80 °C) and thawed 3 times before being centrifuged at
3000 rpm for 20min. The supernatant was then centrifuged through a30% sucrose cushion at 27,000 rpm for 3 h at 4 °C. The supernatant was
removed and virus was resuspended in a total of 2 mL of PBS,
aliquoted, and stored at −20 °C. ELISA plates were coated with
puriﬁed MNV-1 particles and stored at −20 °C until use. Sera was
serially diluted at least four times and tested in triplicate. The primary
antibody, horseradish peroxidase-conjugated, goat anti-mouse IgG
(heavy and light chains, Biorad, Hercules, CA), was diluted 1:1000. The
substrate 2,2′-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid (ABTS;
Calbiochem, Gibbstown, NJ) was added and chemiluminescence was
measured at 405 nm by a Biorad Benchmark Plus spectrophotometer
(Biorad). The data was acquired using the Microplate Manager 5.2
software program (Biorad). Some sera samples were also sent for
commercial testing to the University of Missouri Research Animal
Diagnostic Laboratory (RADIL; Columbia, MO). All mice were tested
for MNV seropositivity before use in an experiment and at the end of
the experiment.
Statistics
Unpaired, two-tailed t-tests were used to analyze the statistical
signiﬁcance of MCMV-speciﬁc CD8 T cell responses. Responses of
b0.5% of all CD8-α+ T cells were not reliably above background, and
when the mean response to an epitope was below 0.5%, statistical
analysis was not performed. The non-parametric Mann Whitney test
was used to analyze organ viral titers when at least one sample per
treatment contained virus above the limit of detection. All statistical
analyses were performed using GraphPad Prism (La Jolla, CA).
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